4º Curso Online de Uveitis: Tratamiento Inmunomodulador en uveítis no infecciosas

27 Junio 2024 (1930 CET TIME)

(Gratuito para socios SEIOC)
 Ricardo Blanco

Ricardo Blanco

Jefe de Servicio de Reumatología

Chairman of Rheumatology Service. Marqués de Valdecilla University Hospital. https://www.humv.es/servicios-y-unidades-asistenciales/reumatologia/

Professor of Medicine, School of Medicine. University of Cantabria.

Head of CSUR, autoimmune diseases reference center of Spanish National Health Service. 

Co-Head and Principal Investigator of Immunopathology Group. Biomedical Research Institute (IDIVAL). https://portalinvestigacion.idival.org/grupos/73

PhD. Director of several PhD. Author of numerous conferences, conference communications and book chapters on different diseases, especially inflammatory. 

Co-author of more than 450 indexed publications (PubMed) (ORCID iD) https://orcid.org/0000-0003-2344-2285) (h web of knowledge index of 62) and more than 1000 abstracts in conferences, especially international ones. Of the publications indexed in medline are included in New England J Medicine, The Lancet, Arthritis & Rheumatology, Ophthalmology, American Journal of Ophthalmology, Rheumatology, Seminars in Arthritis & Rheumatism, and others.

Founder and initial coordinator of the basic and advanced vasculitis and uveitis courses of the SER (Spanish Society of Rheumatology). Director of the vasculitis module of the SER master's degree.

Principal investigator of multiple research projects, both competitive public (FISS-Instituto de Salud Carlos III, PI of 4 FISS scholarships) and private.

Principal Investigator of more than 60 clinical trials, especially on Rheumatoid Arthritis, Psoriatic Arthritis, Spondyloarthritis, Systemic Lupus Erythematosus, Giant Cell Arteritis. Participation in therapeutic development with both biologics and small molecules, being co-author of publications in N Eng J Med, Lancet, Lancet Rheumatology, Ann Rheum Dis, Arthritis & Rheumatology, etc.

Own experience with more than 300 patients with JAKINIB (TOFA, BARI, UPA and FILGOTINIB); in clinical practice and/or clinical trial. Also, with risankizumab, guselkumab, secukinumab, deucravacitinib and most of the new molecules in clinical development in Spondyloarthritis and Psoriatic arthritis.